AOD-9604 vs Semaglutide
Ozempic, Wegovy, Rybelsus
AOD-9604 and Semaglutide are both weight loss compounds evaluated on Vial: AOD-9604 is not FDA approved for human use with preclinical evidence, and Semaglutide is an FDA-approved drug with compounding now restricted with FDA-approval-level clinical evidence.
Vial summary · compiled from public records
At a glance
Semaglutide
Sold as Ozempic, Wegovy, Rybelsus
- Category
- Weight Loss
- FDA / legal status
- Compounding Restricted
- Route
- Subcutaneous, oral
Side by side
| Field | AOD-9604 | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Brand names | — | Ozempic, Wegovy, Rybelsus |
| FDA / legal status | Gray Market | Compounding Restricted |
| Evidence tier | Preclinical | FDA Approved |
| Administration route | — | Subcutaneous, oral |
| Compounding access | Not FDA approved, limited regulated access | Compounding limited to documented case-by-case 503A need |
| Providers on Vial | 0 listed | 28 listed |
| Typical price band | Varies by provider | $ to $$ |
Verified providers offering each
Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
AOD-96040 top providers
No surfaceable providers currently list AOD-9604 on Vial.
See all 0 providers offering aod-9604 →About each compound
About AOD-9604
A modified fragment of human growth hormone consisting of amino acids 177-191, this synthetic peptide was designed to retain the lipolytic properties of GH while lacking its growth-promoting and IGF-1-elevating effects. It acts primarily by stimulating lipolysis and inhibiting lipogenesis in adipose tissue. The compound has been investigated in clinical trials for obesity and is also used in some formulations for osteoarthritis, though regulatory approval status varies by jurisdiction.
About Semaglutide
A synthetic glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide mimics the incretin hormone GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. The compound also acts on hypothalamic receptors to reduce appetite and food intake. Primary clinical applications include the management of type 2 diabetes mellitus and chronic weight management in individuals with obesity or overweight with weight-related comorbidities.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.